Sycai Medical

What Sycai Medical does

Sycai Medical (legal entity SYCAI TECHNOLOGIES SL, VAT ID B01808161) is a Barcelona-based medtech company founded in August 2020 by Sara Toledano (CEO), Júlia Rodríguez-Comas (CSO) and Javier García (CTO). The company develops Class IIb CE-marked AI medical device software under EU MDR for non-invasive detection, characterization and longitudinal monitoring of abdominal lesions (pancreas, liver, with kidneys planned) on routine CT scans. The product suite comprises the Sycai Pancreas algorithm (CE-marked October 2024) and LIRVEA for solid liver lesions including HCC, ICC, lymphoma and metastases (CE-marked July 2026), both delivered as a "zero-click" silent assistant fully integrated into hospital PACS/RIS via DICOM, with automatic retrieval and temporal comparison of prior scans and unique-lesion-ID tracking over time. Underlying technology combines convolutional neural networks for detection/segmentation with radiomics-driven machine learning for lesion classification (e.g., mucinous vs non-mucinous pancreatic cystic lesions), trained on 300,000+ images and validated in 30+ peer-reviewed publications across 10+ hospital sites in Spain and Germany.

The company monetizes through a SaaS/recurring enterprise license model sold directly to hospital radiology departments on a quote-based engagement, with no publicly disclosed price tiers. GTM is enterprise field sales with clinical validation partnerships as the primary demand-generation mechanism, supplemented by presence at major radiology congresses (RSNA, SEDIA), peer-reviewed publications, LinkedIn and direct demo requests via the company website. The company has raised over €2.5M to date (≈two-thirds from public grants/awards and ≈one-third from a 2022 equity round with Ship2B Ventures, Athos Capital and BStartup), and is closing a second funding round with continued participation from prior investors and new institutional capital from Draper B1, Lumo, Namarel and Zubi. Current commercial footprint is concentrated in Spain and Germany with stated intent to enter the US market, and the Full Abdomen Platform architecture is positioned to expand into additional organs and pathologies through software updates.

Name

Sycai Medical

Legal name

SYCAI TECHNOLOGIES SL

Website

https://sycaimedical.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Sycai Medical is a Barcelona-based medtech company that develops CE-marked Class IIb AI software for detecting and longitudinally tracking pancreatic and liver lesions on routine CT scans, delivered as a zero-click PACS-integrated assistant to European hospital radiology departments.

Ownership category

akta.pro rank

Product category

Medical Imaging AI Software

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)

akta.pro secondary industries

Medical Imaging AI (HDAAAEAH), Imaging Interoperability & Standards Enablement (DICOM/HL7/FHIR/IHE) (HLACALAJ), Picture Archiving & Communication Systems (PACS) (HLACALAA)

Keywords

• AI medical imaging
• Radiology workflow software
• Cancer detection software
• Medical device software
• Radiomics analysis

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Medical Device Software Licensing: SaaS licensing model for AI medical device software integrated into hospital PACS systems. Class IIb medical device under MDR with CE marking for pancreas and liver products.

Distribution channels2 records

Marketing channels6 records

Core offering

Sycai Medical develops and sells CE-marked Class IIb AI medical device software that assists radiologists in detecting, characterizing, and longitudinally tracking pre-cancerous abdominal lesions (pancreas, liver, kidneys) on routine CT scans. The software is fully integrated into hospital PACS and RIS systems via DICOM, operates as a zero-click silent assistant, and is licensed to hospitals on a subscription/SaaS basis.

Product overview

Sycai Medical offers two CE-marked Class IIb medical device software products under MDR: SYCAI MEDICAL for pancreatic lesion detection and LIRVEA™ for liver lesion detection. Both products share a unified full abdomen AI platform that operates as a zero-click PACS-integrated assistant analyzing routine CT scans. The platform provides opportunistic screening by detecting incidental findings radiologists may not be actively searching for, with automatic temporal lesion tracking. Current portfolio covers pancreas and liver with planned expansion to kidneys. The products are validated with 30+ scientific publications and 300,000+ training images.

Differentiator

Problem solved

Functional benefit

Brands

• LIRVEA™: AI-powered solution for the detection and monitoring of solid liver lesions using routine abdominal CT scans, Class IIb medical device with CE marking under MDR

Products and services

• SYCAI MEDICAL (Pancreas) CE-marked Class IIb AI medical device software that assists radiologists in detecting and characterizing pancreatic lesions (including pancreatic cystic lesions) on routine CT scans, with temporal lesion tracking and zero-click PACS/RIS integration; for hospital radiology departments.
• LIRVEA (Liver) CE-marked Class IIb AI medical device software for detection and longitudinal monitoring of solid liver lesions including hepatocellular carcinoma, intrahepatic cholangiocarcinoma, lymphomas, and liver metastases on routine abdominal CT scans; for hospital radiology departments.
• Full Abdomen AI Platform Unified multi-organ AI platform currently covering pancreas and liver with planned expansion to kidneys; supports opportunistic screening of routine CT scans for incidental findings and runs as a zero-click silent assistant inside hospital PACS/RIS.

Quantifiable outcome

• Pancreatic lesion detection sensitivity of 96.6% and specificity of 84.5%
• +6 more outcomes

Named customers5 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability7 records

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• deepccoreTechnology or Integration · 1 January 2024AI Operating System platform partnership for DARE-KPL project. Deepc's AI platform enables seamless integration of Sycai's digital assistant into existing healthcare IT systems, allowing quick adoption in healthcare centers.
• University Hospital ErlangencoreStrategic or Co-development Partner · 1 January 2024Eurostars DARE-KPL project collaborator. Radiology department provided clinical expertise and real-world validation environment for AI digital assistant for pancreatic, kidney, and liver focal lesions.
• Hospital de MatarócoreStrategic or Co-development PartnerMulticenter study collaborator for radiomics-based pancreatic cystic lesion classification. Validation of AI tool on external datasets with Dr Mayte Fernández Planas and Dr Montserrat Duh.
• Hospital Universitari Dr Josep TruetacoreStrategic or Co-development PartnerMulticenter study partner for mucinous/non-mucinous pancreatic cystic lesion classification.
• Hospital de la Santa Creu i Sant PaucoreStrategic or Co-development PartnerAdvanced Medical Imaging, AI, and Imaging-Guided Therapy Research Group collaboration for liver lesion review publication. Validation center for pancreatic lesion detection.
• Vall d'Hebron University HospitalcoreStrategic or Co-development PartnerClinical study collaboration for pancreatic cystic lesion detection. Dr Andreu Antolín presented validation results at XXIV SEDIA Congress showing 91.4% detection accuracy.
• Uniklinikum ErlangencoreStrategic or Co-development PartnerInternational validation site for pancreatic lesion detection, in addition to University Hospital Erlangen partnership.
• Cátedra CAMELIA (Plexus en Inteligencia Artificial aplicada a la Medicina Personalizada de Precisión)minorStrategic or Co-development PartnerResearch collaboration with CiTIUS, University of Santiago de Compostela. CEO Sara Toledano participated in Clinical AI Spotlight interview about early abdominal cancer detection.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Viz.ai: AI-powered care coordination and image analysis platform with FDA-cleared algorithms and deep PACS integration. Comparable as a venture-scale, well-funded radiology AI vendor focused on time-sensitive clinical decision support.
• Annalise.ai: Radiology AI platform providing comprehensive AI decision-support across multiple anatomies and modalities, integrated into hospital PACS workflows. Closely comparable as a multi-organ radiology AI vendor with PACS integration and CE-marked clinical products.
• Qure.ai: AI company developing deep-learning solutions for medical imaging, including CT-based detection of lung, head, and chest pathologies. Directly comparable as a multi-modality radiology AI vendor with similar regulatory footprint and hospital customer base.
• Lunit: Korean publicly-listed medical AI company providing AI solutions for cancer detection including lung and breast imaging, with CE-marked and FDA-cleared products. Comparable as a global radiology AI vendor with similar clinical focus on cancer detection.
• Aidoc: Well-funded AI radiology company offering a broad suite of FDA-cleared and CE-marked AI algorithms integrated into PACS for triage and detection. Comparable as a venture-scale radiology AI vendor competing for the same hospital IT procurement budgets.
• Incepto: European AI platform that curates and distributes third-party radiology AI applications into hospital workflows, and where new Sycai CEO Alfonso Martínez previously held a senior role. Closely comparable as a PACS-integrated European radiology AI vendor.
• Aidence: European radiology AI company developing deep-learning solutions for lung nodule and CT-based cancer detection. Directly comparable as a venture-stage radiology AI vendor selling to European hospital radiology departments with similar AI/CV technology stack.

Broad incumbents

• GE HealthCare: Global incumbent in medical imaging equipment and enterprise imaging IT with rapidly expanding AI capabilities embedded across its PACS and modality portfolio. Comparable as the dominant PACS vendor Sycai must integrate with — and a potential competitive threat if it bundles native AI.
• Philips HealthSuite / Philips Radiology: Major incumbent in radiology informatics (PACS/RIS) and medical imaging, with growing AI-enabled decision support integrated into its enterprise imaging platform. Comparable as a PACS/RIS vendor whose installed base defines the integration surface Sycai relies upon.

Regional players

• Perspectum: UK-based medical imaging company offering AI-driven quantitative imaging analysis, primarily in liver and abdominal indications. Comparable in clinical focus (liver and abdominal disease) and integrated PACS workflow, but primarily serves UK and US markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/sycaimedical

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sycai Medical